Showing results (431-440 of 5,984) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|December 17, 2002
Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cellsDanyelle M Townsend, Hongxie Shen, Alexandra L Staros, et al.
Molecular Cancer Therapeutics|July 30, 2021
Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer CellsAlan P Lombard, Wei Lou, Cameron M Armstrong, et al.
Molecular Cancer Therapeutics|July 28, 2021
SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation StatusKenji M Fujihara, Mariana Corrales Benitez, Carlos S Cabalag, et al.
Molecular Cancer Therapeutics|July 28, 2021
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding AgentFinith Jernigan, Arthur Branstrom, John D Baird, et al.
Molecular Cancer Therapeutics|November 11, 2018
Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell LymphomaCarrie J Li, Changying Jiang, Yang Liu, et al.
Molecular Cancer Therapeutics|October 25, 2018
Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung CancerFrank Aboubakar Nana, Marylène Lecocq, Maha Zohra Ladjemi, et al.
Molecular Cancer Therapeutics|October 25, 2018
Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP InhibitionHaihong Zhong, Cui Chen, Ravinder Tammali, et al.
Molecular Cancer Therapeutics|October 25, 2018
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical PropertiesLiangxian Cao, Marla Weetall, Christopher Trotta, et al.
Molecular Cancer Therapeutics|March 26, 2017
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family InhibitorTimothy P S Perera, Eleonora Jovcheva, Laurence Mevellec, et al.
Molecular Cancer Therapeutics|March 26, 2017
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF AntibodyPamela J Farrell, Jennifer Matuszkiewicz, Deepika Balakrishna, et al.
Pageof 599